Poor
Not Aligned
Patient Risk:
Low
Summary
Only a subset of clinical/mechanism and indication statements are supported by the provided FDA label sections. Multiple other claims (pricing, patient assistance program, approval year, and external patent database assertions, plus several mechanistic/general oncology comparisons and specific side effects) are not supported by the provided label text and therefore substantially reduce overall alignment.
Category Scores
Accurate Statements
Vizimpro is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) with specific genetic mutations.
Supported by 1 INDICATIONS AND USAGE.
Vizimpro works by inhibiting epidermal growth factor receptor (EGFR) activity.
Supported by 12.1 Mechanism of Action.
Vizimpro is approved by the FDA for the treatment of patients with metastatic NSCLC whose tumors have an EGFR exon 19 deletion.
Supported by 1 INDICATIONS AND USAGE.
Vizimpro is approved by the FDA for the treatment of patients with metastatic NSCLC whose tumors have an EGFR exon 21 L858R substitution.
Supported by 1 INDICATIONS AND USAGE.
Vizimpro is an irreversible tyrosine kinase inhibitor (TKI) that targets EGFR.
Supported by 12.1 Mechanism of Action.
Vizimpro is used for patients with specific EGFR mutations.
Supported by 1 INDICATIONS AND USAGE and 12.1 Mechanism of Action.
Common side effects of Vizimpro include diarrhea.
Partially supported by 5.2 Diarrhea (includes incidence/severity but label section describes adverse event rather than using the term 'common').
Common side effects of Vizimpro include rash.
Partially supported by 5.3 Dermatologic Adverse Reactions (includes incidence; adverse reaction described rather than explicitly 'common').
More serious side effects may also occur with Vizimpro treatment.
Supported generally by the presence of serious warnings/precautions in 5.1–5.3.
Unsupported Statements
Vizimpro (dacomitinib) price can vary depending on dosage, quantity, and the pharmacy where it is purchased.
No support in the provided label sections; pricing/market mechanics are not described in the supplied FDA labeling text.
Manufacturer-reported prices for a 30-day supply of Vizimpro 45 mg tablets can range from approximately $11,500 to $11,600.
No FDA label support for specific dollar ranges or manufacturer-reported price figures in the provided text.
Vizimpro pricing is influenced by specific dosage strength and the number of tablets included in a prescription.
No provided label support for pricing determinants.
Differences in Vizimpro pricing can be observed between various retail pharmacies.
No provided label support for retail pharmacy price variability.
Patient assistance programs and insurance coverage affect individuals' out-of-pocket cost for Vizimpro.
No provided label support for patient assistance/insurance out-of-pocket cost statements.
Pfizer, the manufacturer of Vizimpro, offers the Pfizer Oncology Together program.
No provided label support for manufacturer-sponsored program names.
The Pfizer Oncology Together program can provide financial support for eligible patients prescribed oncology medications.
No provided label support for financial assistance program details.
In some NSCLC cells, EGFR is overactive and promotes cancer cell growth and division.
Not supported by the provided label excerpts.
Vizimpro blocks the EGFR signaling pathway.
Not explicitly supported by the provided label excerpts (12.1 describes irreversible inhibition of kinase activity, not the exact wording 'blocks the signaling pathway').
Vizimpro was approved by the U.S. Food and Drug Administration (FDA) in 2018.
Approval year is not supported by the provided label sections.
Gefitinib and erlotinib are reversible TKIs.
Not supported by the provided label excerpts.
Gefitinib and erlotinib were among earlier targeted therapies approved for NSCLC with EGFR mutations.
Not supported by the provided label excerpts.
Osimertinib is a newer generation EGFR inhibitor.
Not supported by the provided label excerpts.
Osimertinib may be used in different lines of treatment or for specific resistance mutations.
Not supported by the provided label excerpts.
The choice of therapy depends on the specific mutation profile of the cancer and the patient's clinical situation.
Not supported by the provided label excerpts.
Common side effects of Vizimpro include acne.
No provided label support for acne as an adverse reaction.
Common side effects of Vizimpro include stomatitis (mouth sores).
No provided label support for stomatitis/mouth sores.
Information regarding the patent status and potential patent expiry for Vizimpro can be found through specialized drug patent databases.
No provided label support for patent-database guidance.
DrugPatentWatch.com provides patent information for pharmaceutical products, including granted patents and expiration dates.
No provided label support for this specific external website.
DrugPatentWatch.com provides information that can indicate when generic versions of a drug might become available.
No provided label support for this specific external website or generics-timing claims.
Contradictions
Important Omissions
The AI response did not provide label-supported dosage, dose modification, or administration instructions (even though some claims focus on side effects).
Importance:
Moderate
No label-supported monitoring/management specifics for adverse reactions (e.g., ILD monitoring and diarrhea management with withholding/resume criteria) were provided in the AI response, despite making broad safety/side-effect assertions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are largely non-label financial/patent/general comparison statements rather than dosing instructions. However, multiple unsupported mechanistic/generalization and adverse-effect 'common side effects' claims could mislead readers if treated as label-backed information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous claims are not supported by the provided FDA prescribing information (pricing/program/patent database/approval year and several adverse-event items and mechanistic generalizations).
Suggested Improvement
Restrict statements to the label-supported indication and mechanism sections provided; remove or clearly separate non-label financial, program, patent, and external comparison content, and only list adverse reactions explicitly described in the provided label excerpts.